|
1.
|
Jemal A, Siegel R, Ward E, Murray T, Xu J,
Smigal C and Thun MJ: Cancer Statistics. CA Cancer J Clin.
56:106–130. 2006.
|
|
2.
|
Jemal A, Siegel R, Ward E, Hao Y, Xu J and
Thun MJ: Cancer statistics, 2009. CA Cancer J Clin. 59:225–249.
2009. View Article : Google Scholar
|
|
3.
|
Jin YT, Xu YC, Yang RD, Huang CF, Xu CW
and He XZ: Familial aggregation of lung cancer in a high incidence
area in China. Br J Cancer. 92:1321–1325. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
4.
|
Parkin DM, Bray F, Ferlay J and Pisani P:
Estimating the world cancer burden: Globocan 2000. Int J Cancer.
94:153–156. 2001. View
Article : Google Scholar : PubMed/NCBI
|
|
5.
|
Jemal A, Tiwael RC, Murray T, et al:
Cancer statistics. CA Cancer J Clin. 54:92–119. 2004.
|
|
6.
|
Hirsch FR, Merrick DT and Franklin WA:
Role of biomarkers for early detection of lung cancer and
chemoprevention. Eur Respir J. 19:1151–1158. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
7.
|
Anglim PP, Alonzo TA and Laird-Offringa
IA: DNA methylation-based biomarkers for early detection of
non-small cell lung cancer: an update. Mol Cancer. 23:812008.
View Article : Google Scholar : PubMed/NCBI
|
|
8.
|
Nephew KP: What will it take to obtain DNA
methylation markers for early cervical cancer detection. Gynecol
Oncol. 112:291–292. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9.
|
Zhang Y, Wang R, Song H, Huang G, Yi J,
Zheng Y, Wang J and Chen L: Methylation of multiple genes as a
candidate biomarker in non-small cell lung cancer. Cancer Lett.
303:21–28. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10.
|
Choi JE, Kim DS, Kim EJ, Chae MH, Cha SI,
Kim CH, Jheon S, Jung TH and Park JY: Aberrant methylation of
ADAMTS1 in non-small cell lung cancer. Cancer Genet Cytogenet.
187:80–84. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11.
|
Burbee DG, Forgacs E, Zochbauer-Muller S,
Shivakumar L, Fong K and Gao B: Epigenetic inactivation of RASSF1A
in lung and breast cancers and malignant phenotype suppression. J
Natl Cancer Inst. 93:691–699. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Honorio S, Agathanggelou A, Schuermann M,
Pankow W, Viacava P and Maher ER: Detection of RASSF1A aberrant
promoter hypermethylation in sputum from chronic smokers and ductal
carcinoma in situ from breast cancer patients. Oncogene.
22:147–150. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
13.
|
Grote HJ, Schmiemann V, Geddert H, Bocking
A, Kappes R and Gabbert HE: Methylation of RAS association domain
family protein 1A as a biomarker of lung cancer. Cancer.
108:129–134. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Wang Y, Yu Z, Wang T, Zhang J, Hong L and
Chen L: Identification of epigenetic aberrant promoter methylation
of RASSF1A in serum DNA and its clinicopathological significance in
lung cancer. Lung Cancer. 56:289–294. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
15.
|
Maruyama R, Toyooka S, Toyooka KO, et al:
Aberrant promoter methylation profile of prostate cancers and its
relationship to clinicopathological features. Clin Cancer Res.
8:514–519. 2002.PubMed/NCBI
|
|
16.
|
Neyaz MK, Kumar RS, Hussain S, et al:
Effect of aberrant promoter methylation of FHIT and RASSF1A genes
on susceptibility to cervical cancer in a North Indian population.
Biomarkers. 13:597–606. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17.
|
Baylin SB: DNA methylation and gene
silencing in cancer. Nat Clin Pract Oncol. 2(Suppl 1): 4–11. 2005.
View Article : Google Scholar
|
|
18.
|
Hesson LB, Cooper WN and Latif F: The role
of RASSF1A methylation in cancer. Dis Markers. 23:73–87. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
19.
|
Fischer JR, Ohnmacht U, Rieger N, Zemaitis
M, Stoffregen C, Kostrzewa M, Buchholz E, Manegold C and Lahm H:
Promoter methylation of RASSF1A, RARbeta and DAPK predict poor
prognosis of patients with malignant mesothelioma. Lung Cancer.
54:109–116. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
20.
|
Toyooka S, Suzuki M, Maruyama R, Toyooka
KO, Tsukuda K, Fukuyama Y, Iizasa T, Aoe M, Date H, Fujisawa T,
Shimizu N and Gazdar AF: The relationship between aberrant
methylation and survival in non-small-cell lung cancers. Br J
Cancer. 91:771–774. 2004.PubMed/NCBI
|
|
21.
|
Toyooka S, Suzuki M, Tsuda T, Toyooka KO,
Maruyama R, Tsukuda K, Fukuyama Y, Iizasa T, Fujisawa T, Shimizu N,
Minna JD and Gazdar AF: Dose effect of smoking on aberrant
methylation in non-small cell lung cancers. Int J Cancer.
110:462–464. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
22.
|
Toyooka S, Maruyama R, Toyooka KO,
McLerran D, Feng Z, Fukuyama Y, Virmani AK, Zochbauer-Muller S,
Tsukuda K, Sugio K, et al: Smoke exposure, histologic type and
geography-related differences in the methylation profiles of
non-small cell lung cancer. Int J Cancer. 103:153–160. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
23.
|
Shaw RJ, Liloglou T, Rogers SN, Brown JS,
Vaughan ED, Lowe D, Field JK and Risk JM: Promoter methylation of
P16, RARbeta, E-cadherin, cyclin A1 and cytoglobin in oral cancer:
quantitative evaluation using pyrosequencing. Br J Cancer.
94:561–568. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
24.
|
Chan EC, Lam SY, Tsang KW, Lam B, Ho JC,
Fu KH, Lam WK and Kwong YL: Aberrant promoter methylation in
Chinese patients with non-small cell lung cancer: patterns in
primary tumors and potential diagnostic application in
bronchoalveolar lavage. Clin Cancer Res. 8:3741–3746.
2002.PubMed/NCBI
|
|
25.
|
Fujiwara K, Fujimoto N, Tabata M, Nishii
K, Matsuo K, Hotta K, Kozuki T, Aoe M, Kiura K, Ueoka H and
Tanimoto M: Identification of epigenetic aberrant promoter
methylation in serum DNA is useful for early detection of lung
cancer. Clin Cancer Res. 11:1219–1225. 2005.PubMed/NCBI
|
|
26.
|
Virmani AK, Rathi A, Zöchbauer-Müller S,
Sacchi N, Fukuyama Y, Bryant D, Maitra A, Heda S, Fong KM,
Thunnissen F, Minna JD and Gazdar AF: Promoter methylation and
silencing of the retinoic acid receptor-beta gene in lung
carcinomas. J Natl Cancer Inst. 92:1303–1307. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
27.
|
Zöchbauer-Müller S, Minna JD and Gazdar
AF: Aberrant DNA methylation in lung cancer: biological and
clinical implications. Oncologist. 7:451–457. 2002.PubMed/NCBI
|
